Hyloris Pharmaceuticals SA partners with China’s Grand Life Sciences
LIEGE: Belgian biopharmaceutical company Hyloris Pharmaceuticals SA said on Monday it has signed an exclusive license and distribution agreement with China’s Grand Life Sciences Group Co., Ltd. for HY-094, its investigational injectable iron therapy. The partnership grants Grand Life Sciences the rights to develop and commercialize HY-094 in China, a market for intravenous (IV) iron…